A Phase 1 Dose Escalation Study of TTI-237 Administered Intravenously Every 3 Weeks in Subjects With Advanced Malignant Solid Tumors
Phase 1
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Neoplasms
Both
Neoplasms
Trial Information
A Phase 1 Dose Escalation Study of TTI-237 Administered Intravenously Every 3 Weeks in Subjects With Advanced Malignant Solid Tumors
Inclusion Criteria:
- Documented diagnosis of malignant solid tumor with measurable disease
- Life expectancy of at least 12 weeks
- ECOG performance status of 0, 1, or 2
Exclusion Criteria:
- Recent major surgery, radiation therapy or anti-cancer treatment
- History of any other prior malignancy within the last 5 years
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Primary purpose is to address the safety and tolerability of TTI-237. Patient will be assessed on an ongoing basis during their participation on the trial.
Principal Investigator
Medical Monitor
Investigator Role:
Study Director
Investigator Affiliation:
Wyeth is now a wholly owned subsidiary of Pfizer
Authority:
United States: Food and Drug Administration
Study ID:
3162K1-101
NCT ID:
NCT00195247
Start Date:
May 2005
Completion Date:
Related Keywords:
- Neoplasms
- Tumors
- Advanced malignant solid tumors
- Neoplasms
Name | Location |
|---|---|
| Phoenix, Arizona 85012 | |
| Fountain Valley, California 92708 | |
| Baltimore, Maryland 21287 |
